

Launching your R&D Career: Insights from Industry Leaders, with Networking

Where Do I Go From Yale? Alumni Panel ~ April 1, 2025

Discover what it takes to transition from academia to industry in this exclusive 1-hour virtual event featuring top R&D leaders, biotech innovators, and chief medical officers—all Yale alumni! You'll hear advice on career paths in R&D in biotech and pharma, hear inspiring professional journeys from the panelists, and learn about how to land your first role in industry. Engage directly with these industry R&D leaders through Q&A and networking breakout sessions where you can meet the leaders personally. Don't miss this opportunity to kickstart your career with guidance from this virtual session!

Eric Hughes '98 PhD (Immunobiology), '99 MD



Eric A. Hughes, MD, PhD, is Executive Vice President, Global R&D, and Chief Medical Officer at Teva. A physician-scientist specializing in infectious diseases and immunology, he has nearly 20 years of experience in drug development at leading pharmaceutical companies. He earned his MD and PhD at Yale, completed his residency at Yale New Haven Hospital, and pursued a fellowship in infectious diseases at Yale School of Medicine.

[LinkedIn](#)

Robert Iannone '93 MD



Robert Iannone, is a board-certified pediatric hematologist-oncologist and pharmaceutical executive. After earning his MD from Yale and training at Johns Hopkins, he pursued academic medicine before transitioning to drug development. He held leadership roles at Merck, AstraZeneca, and Immunomedics, leading oncology innovations. Now EVP & Global Head of R&D at Jazz Pharmaceuticals, he oversees neuroscience and oncology advancements. He also serves on biotech boards and advisory committees.

[LinkedIn](#)

Gregg Keaney '05 PhD (Chemistry)



Gregg is the Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Product Development at Rapport Therapeutics. He is an entrepreneurial drug hunter who has been one of the early employees at several Boston-area biotech companies with roles spanning across the drug development and discovery spectrum. Gregg has previously held positions of increasing responsibility at Third Harmonic Bio, Cadent Therapeutics, Ataxion Therapeutics, H3 Biomedicine, and Infinity Pharmaceuticals.

[LinkedIn](#) | [Cross Campus](#)

Ken Takeshita '84 MD



Ken has been the Global Head of Research & Development for Daiichi Sankyo since 2021. Before Daiichi Sankyo, Ken served as Head of Development at Kite Pharma and led development programs at Celgene and Amgen. Ken was previously on the hematology faculty at Yale School of Medicine and NYU School of Medicine. He has an AB in Molecular Biology from Harvard and an MD from Yale. He received post-doctoral training in hematology and developmental biology at Yale and University of Tokyo.



[LinkedIn](#)

Moderator: Marisa Dolled-Filhart '05 PhD (Genetics)



Marisa Dolled-Filhart, Ph.D. is a drug development and precision medicine leader, currently Global Team Leader at Daiichi Sankyo, leading oncology drug development teams. Previously, she was VP of Translational Research at BMS and has held prior biomarker and diagnostic roles at Merck, IQVIA and HistoRx. She has 95+ publications, received the 2024 HBA Luminary Award, and is on the Yale GSAS Alumni Association Board. Marisa holds a B.A. from Cornell and a Ph.D. in Genetics from Yale.

[LinkedIn](#) | [Cross Campus](#)